Document is current
Any future updates will be listed below
-
Authors
Hartman, Heidi S. https://orcid.org/0000-0002-5154-0221
Finer, Joshua https://orcid.org/0009-0002-4721-4527
Hartzel, Dustin
Kelsey, Christopher
Long, Aaron
Rocha, Daniel
Ruhl, Jeffrey A. https://orcid.org/0000-0002-8741-979X
vanMaanen, David
Malta, Paloma P. https://orcid.org/0009-0006-3795-829X
Castillo, Michelle
Roedan Oliver, Francisco A.
Daniels, Brock
Hughes, John Weston
Leon, Martin B.
Probst, Marc A. https://orcid.org/0000-0002-1503-7178
Poterucha, Timothy J.
Elias, Pierre https://orcid.org/0000-0002-9643-3024
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health
Edwards Lifesciences
- License Information
-
More Information
Article History
First Online: 22 June 2026
Competing interests
: T.J.P. owns stock in Abbott Laboratories and Baxter International, and has research support provided to his affiliated institutions from the Tianqiao & Chrissy Chen Institute, American Heart Association (awards 933452 and 23SCISA1077494) Eidos Therapeutics, Pfizer, Janssen Pharmaceuticals and Edwards Lifesciences. T.J.P. and P.E. are inventors of the AI-ECG algorithm “EchoNext” for the detection of structural heart disease. P.E. has received research support to his institution from the American Heart Association, Eidos Therapeutics, Pfizer, Janssen Pharmaceuticals, New York Academy of Medicine, Edwards Lifesciences, and owns equity in Pathway Labs. M.A.P. is supported by a grant from the NIH/NHLBI (R01HL149680). All other authors declare no competing interests.
